Previous efforts to circumvent the problem of the size limitation imposed by the AAV vector have focused mainly on altering the candidate genes into ‘mini-expression cassettes’ suitable for ...

SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of ...

Next-generation sequencing allows for critical insights into gene therapy products, which can help streamline and accelerate ...

Viral Vector Development MarketThe Viral Vector Development Market is set for impressive growth, with its valuation expected to rise from USD 730.7 million in 2023 to USD 4.1 billion by 2033, ...

Adeno-associated viral (AAV) vectors in particular have high transduction rates and reduced toxicity concerns compared to other viral vectors. However, these delivery vehicles present some application ...

A research group of The University of Tokyo has discovered that in mammals, a protein kinase A (PKA) promotes wakefulness, ...

In the groundbreaking study the researchers observed an annualised zero bleeding rate in all the five subjects enrolled with ...

US FDA grants Orphan Drug Designation to AAVantgarde Bio’s AAVB-081 to treat Usher Syndrome Type 1B retinitis pigmentosa: Milan, Italy Tuesday, December 3, 2024, 16:00 Hrs [IST] ...

Click here to read the article now. Delandistrogene moxeparvovec uses an adeno-associated viral (AAV) vector to deliver a ...

The U.S. Food and Drug Administration has approved PTC Therapeutics' Kebilidi (eladocagene exuparvovec-tneq) for the ...

MILAN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector ...